lentiboost-review1920x640
Literature - Publication Review

Empowering T cell therapies: the strategic use of LentiBOOST in CAR T and TCR modalities

A crucial step in the development of ACTs is the genetic modification of immune cells. One widely adopted method involves the use of lentiviral vectors, which are known for their efficiency in integrating therapeutic genes into target cell genomes.

Learn how the LentiBOOST™ transduction enhancer is being applied to CAR T and TCR modalities by scientists around the globe in this literature review.

You will read about applications in:

  • Allogeneic CAR T-cell production
  • CAR T-cells targeting ovarian cancer
  • CAR-Treg transduction
  • Dual-targeting CAR T-cell manufacturing
  • TCR gene delivery and function in cord blood-derived T cells

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Empowering T cell therapies: the strategic use of LentiBOOST in CAR T and TCR modalities

Download Literature - Publication Review